These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 17683001)

  • 1. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2010 May; 50(10):1415-8. PubMed ID: 20377409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Puthanakit T; Aurpibul L; Yoksan S; Sirisanthana T; Sirisanthana V
    Vaccine; 2007 Nov; 25(49):8257-61. PubMed ID: 17964009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children.
    Berkelhamer S; Borock E; Elsen C; Englund J; Johnson D
    Clin Infect Dis; 2001 Apr; 32(7):1090-4. PubMed ID: 11264038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Siriaksorn S; Sirisanthana T; Sirisanthana V
    HIV Med; 2006 Oct; 7(7):467-70. PubMed ID: 16925733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
    Lao-Araya M; Puthanakit T; Aurpibul L; Taecharoenkul S; Sirisanthana T; Sirisanthana V
    Vaccine; 2011 May; 29(23):3977-81. PubMed ID: 21473954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
    Belaunzarán-Zamudio PF; García-León ML; Wong-Chew RM; Villasís-Keever A; Cuellar-Rodríguez J; Mosqueda-Gómez JL; Muñoz-Trejo T; Escobedo K; Santos JI; Ruiz-Palacios GM; Sierra-Madero JG
    Vaccine; 2009 Nov; 27(50):7059-64. PubMed ID: 19799846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
    Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
    J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development Study.
    Hilgartner MW; Maeder MA; Mahoney EM; Donfield SM; Evatt BL; Hoots WK
    Am J Hematol; 2001 Feb; 66(2):92-8. PubMed ID: 11421305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Song LY; Fenton T; Nachman SA; Levin MJ; Rosenblatt HM; Pelton SI; Borkowsky W; Edwards KM; Peters J;
    Pediatrics; 2007 Nov; 120(5):e1190-202. PubMed ID: 17938165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy.
    Lao-araya M; Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
    Vaccine; 2007 Jul; 25(29):5324-9. PubMed ID: 17566615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.